Toltrazuril is a synthetic compound in the triazine class that has been described in veterinary research related to protozoal parasites such as Eimeria and Sarcocystis.
It is not approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, cure, mitigation, treatment, or prevention of any animal disease.
Information on this page is for educational purposes only and does not constitute medical advice.
Any use must be directed by a licensed veterinarian.
Toltrazuril is a synthetic compound classified within the triazine group of chemicals. It is the parent compound of ponazuril (toltrazuril sulfone), which is its primary active metabolite.
Published, third-party research literature has described its mechanism of action in laboratory settings. These non-clinical studies have investigated its effects on the intracellular developmental stages of certain protozoa, including schizonts and gametes.
These findings are for academic and research reference only and should not be interpreted as claims of clinical effectiveness. This substance is not an FDA-approved drug.
Toltrazuril has been the subject of numerous third-party, international academic studies for over two decades. This research, which does not imply FDA approval, has been published in various veterinary and parasitology journals.
The body of research includes laboratory (in vitro) studies and international field studies (in vivo) across a wide range of animal species, including poultry, canines, felines, and reptiles.
It is important to note that while Toltrazuril is an unapproved new animal drug in the United States , it is approved for specific uses in other countries, such as for coccidiosis in poultry within the European Union
In the United States, Toltrazuril is classified as a Bulk Drug Substance (BDS). Its use is restricted to compounding by a licensed veterinarian or pharmacist under the specific, patient-prescribed conditions outlined in the FDA's Guidance for Industry (GFI) #256
